Zurich Cantonal Bank’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-10,613
Closed -$11K 2650
2024
Q3
$11K Sell
10,613
-2,921
-22% -$4.01K ﹤0.01% 2611
2024
Q2
$23.4K Sell
13,534
-1,988
-13% -$4K ﹤0.01% 2586
2024
Q1
$37.1K Sell
15,522
-21,201
-58% -$52.2K ﹤0.01% 2594
2023
Q4
$122K Buy
36,723
+10,238
+39% +$27.4K ﹤0.01% 2351
2023
Q3
$99.1K Sell
26,485
-2,107
-7% -$9.73K ﹤0.01% 2355
2023
Q2
$122K Buy
28,592
+45
+0.2% +$266 ﹤0.01% 2245
2023
Q1
$195K Sell
28,547
-1,651
-5% -$12.8K ﹤0.01% 1874
2022
Q4
$239K Sell
30,198
-358
-1% -$2.75K ﹤0.01% 1724
2022
Q3
$294K Sell
30,556
-1,279
-4% -$12.9K ﹤0.01% 1524
2022
Q2
$230K Sell
31,835
-1,430
-4% -$12.4K ﹤0.01% 1705
2022
Q1
$429K Buy
33,265
+1,069
+3% +$13.6K ﹤0.01% 1429
2021
Q4
$514K Buy
32,196
+189
+0.6% +$3.31K ﹤0.01% 1426
2021
Q3
$514K Sell
32,007
-544
-2% -$7.97K ﹤0.01% 1276
2021
Q2
$450K Buy
32,551
+1,174
+4% +$16.6K ﹤0.01% 1287
2021
Q1
$458K Buy
31,377
+22,067
+237% +$375K ﹤0.01% 1286
2020
Q4
$162K Hold
9,310
﹤0.01% 1963
2020
Q3
$171K Hold
9,310
﹤0.01% 1718
2020
Q2
$166K Buy
9,310
+4,693
+102% +$79.4K ﹤0.01% 1633
2020
Q1
$75K Buy
4,617
+990
+27% +$18.3K ﹤0.01% 1757
2019
Q4
$65K Hold
3,627
﹤0.01% 1990
2019
Q3
$73K Hold
3,627
﹤0.01% 1782
2019
Q2
$80K Hold
3,627
﹤0.01% 1748
2019
Q1
$49K Buy
3,627
+326
+10% +$4.35K ﹤0.01% 2016
2018
Q4
$30K Hold
3,301
﹤0.01% 2294
2018
Q3
$54K Buy
3,301
+456
+16% +$8.08K ﹤0.01% 2106
2018
Q2
$40K Buy
2,845
+2,244
+373% +$32.1K ﹤0.01% 2246
2018
Q1
$7K Hold
601
﹤0.01% 2515
2017
Q4
$5K Hold
601
﹤0.01% 2532
2017
Q3
$8K Hold
601
﹤0.01% 2449
2017
Q2
$9K Hold
601
﹤0.01% 2437
2017
Q1
$13K Hold
601
﹤0.01% 2425
2016
Q4
$17K Hold
601
﹤0.01% 2313
2016
Q3
$16K Buy
601
+199
+50% +$5.43K ﹤0.01% 2297
2016
Q2
$7K Hold
402
﹤0.01% 2448
2016
Q1
$9K Hold
402
﹤0.01% 2381
2015
Q4
$9K Hold
402
﹤0.01% 2417
2015
Q3
$8K Buy
+402
New +$12.2K ﹤0.01% 2196

Other funds holding CHRS

Zurich Cantonal Bank's CHRS Position: Q4 2024 in Review

Zurich Cantonal Bank sold out of Coherus Oncology (CHRS) in Q4 2024, closing a stake of 10,613 shares — an estimated $11K sold.

Zurich Cantonal Bank first reported a position in CHRS in Q3 2015 and held it in 37 quarters. The position peaked at $514K in Q4 2021. 124 funds tracked by Wall St. Rank hold CHRS as of Q4 2024.

  • Zurich Cantonal Bank reported no remaining Coherus Oncology position as of Q4 2024 after selling out during the quarter.
  • Zurich Cantonal Bank sold 10,613 Coherus Oncology shares in Q4 2024, an estimated $11K.
  • Zurich Cantonal Bank first reported a position in Coherus Oncology in Q3 2015 and held it in 37 quarters.
  • Zurich Cantonal Bank's Coherus Oncology position peaked at $514K in Q4 2021.
  • 124 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2024.

Based on Zurich Cantonal Bank's 13F filing for Q4 2024, filed 7 Feb 2025.